Chen Xiaojie, Wei Lin, Zhu Zhijun, Sun Liying, Qu Wei, Zeng Zhigui
Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China.
Pediatr Transplant. 2019 Jun;23(4):e13418. doi: 10.1111/petr.13418. Epub 2019 Apr 23.
We introduce the indications, technique, results of our experience using donor's RGEA as interposition vessel to solve hepatic artery reconstruction problems in P-LDLT.
A retrospective analysis of P-LDLT for children with metabolic diseases from June 2013 to November 2018 in our center was carried out. The arterial conditions, reconstruction methods, and prognosis were analyzed.
A total of 73 children with metabolic diseases underwent P-LDLT during the period. The LLF was the main graft, accounting for 71.2%. The donor's RGEA was utilized in five cases. There were three children with OTCD and two children with deficiency of CPS1 and MSUD, respectively. In three cases, the grafts' left hepatic arteries were anastomosed with the recipients' PHA using donors' RGEA as interposition vessel. In other two cases, the donors' RGEA was interposed between graft's MHA and the recipient's bifurcation of PHA and GDA. The average follow-up time was 19.7 ± 15.9 month. There were two cases of artery thrombosis or occlusion, and the incidence was 2.7%. No arterial complications occurred in children using RGEA (follow-up time 5.0 ± 3.4 months).
In P-LDLT for patients with metabolic diseases, the application of RGEA as an interposition vessel can solve caliber mismatch and short arteries problem and achieve good results. Compared with traditional arterial anastomosis, it may reduce the incidence of arterial complications.
介绍我们使用供体右胃网膜动脉(RGEA)作为搭桥血管解决亲体肝移植(P-LDLT)中肝动脉重建问题的适应证、技术及结果。
对2013年6月至2018年11月在本中心接受P-LDLT治疗的代谢性疾病患儿进行回顾性分析。分析动脉情况、重建方法及预后。
在此期间,共有73例代谢性疾病患儿接受了P-LDLT。左外侧叶(LLF)是主要移植物,占71.2%。5例使用了供体的RGEA。其中3例为鸟氨酸转氨甲酰酶缺乏症(OTCD)患儿,2例分别为氨甲酰磷酸合成酶1(CPS1)和枫糖尿病(MSUD)缺乏症患儿。3例中,将移植物的左肝动脉与受体的门静脉左支(PHA)使用供体的RGEA作为搭桥血管进行吻合。另外2例中,供体的RGEA置于移植物的肝中动脉(MHA)与受体的PHA和胃十二指肠动脉(GDA)分叉处之间。平均随访时间为19.7±15.9个月。发生动脉血栓形成或闭塞2例,发生率为2.7%。使用RGEA的患儿未发生动脉并发症(随访时间5.0±3.4个月)。
在代谢性疾病患者的P-LDLT中,应用RGEA作为搭桥血管可解决管径不匹配和动脉过短问题,并取得良好效果。与传统动脉吻合相比,可能降低动脉并发症的发生率。